Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$0.02
-2.9%		$0.03
$0.02
▼
$0.15
N/AN/A5,913 shs3,046 shs
CDTTW
Conduit Pharmaceuticals
$0.01
+3.0%		$0.01
$0.01
▼
$0.02
N/AN/A26,968 shs24,085 shs
CINGW
Cingulate
$0.01
+6.0%		$0.01
$0.00
▼
$0.12
N/AN/A32,190 shs20,125 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.03
-22.9%		$0.03
$0.02
▼
$0.15
N/AN/A9,533 shs8,544 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRIW
Biofrontera
-2.91%-2.91%-31.03%-36.10%-80.22%
CDTTW
Conduit Pharmaceuticals
+3.03%-19.69%+3.03%-32.89%0.00%
CINGW
Cingulate
+18.00%+1.29%-37.89%-70.00%-85.25%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
-22.86%-23.30%+6.72%-10.89%-25.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$0.02
-2.9%		$0.03
$0.02
▼
$0.15
N/AN/A5,913 shs3,046 shs
CDTTW
Conduit Pharmaceuticals
$0.01
+3.0%		$0.01
$0.01
▼
$0.02
N/AN/A26,968 shs24,085 shs
CINGW
Cingulate
$0.01
+6.0%		$0.01
$0.00
▼
$0.12
N/AN/A32,190 shs20,125 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.03
-22.9%		$0.03
$0.02
▼
$0.15
N/AN/A9,533 shs8,544 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRIW
Biofrontera
-2.91%-2.91%-31.03%-36.10%-80.22%
CDTTW
Conduit Pharmaceuticals
+3.03%-19.69%+3.03%-32.89%0.00%
CINGW
Cingulate
+18.00%+1.29%-37.89%-70.00%-85.25%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
-22.86%-23.30%+6.72%-10.89%-25.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera Inc. stock logo
BFRIW
Biofrontera
0.00
N/AN/AN/A
CDTTW
Conduit Pharmaceuticals
0.00
N/AN/AN/A
CINGW
Cingulate
0.00
N/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$46.18MN/AN/AN/AN/AN/A
CDTTW
Conduit Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CINGW
Cingulate
N/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$1.11MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A11/18/2026 (Estimated)
CDTTW
Conduit Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CINGW
Cingulate
N/AN/AN/AN/AN/AN/AN/AN/A11/18/2026 (Estimated)
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/AN/AN/A
CDTTW
Conduit Pharmaceuticals
N/AN/AN/AN/AN/A
CINGW
Cingulate
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/A
CDTTW
Conduit Pharmaceuticals
N/A
CINGW
Cingulate
N/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/A
CDTTW
Conduit Pharmaceuticals
N/A
CINGW
Cingulate
N/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera Inc. stock logo
BFRIW
Biofrontera
70N/AN/ANot Optionable
CDTTW
Conduit Pharmaceuticals
7N/AN/ANot Optionable
CINGW
Cingulate
20N/AN/ANot Optionable
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable

Recent News About These Companies

60 Degrees Advances Babesiosis Treatment With FDA Submission
September 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-advances-babesiosis-treatment-with-fda-submission?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Reports Second Quarter 2026 Financial Results with 106% Increase in Net Product Revenues
August 14, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-shareholders-approve-key-governance-actions?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
August 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-completes-private-placement-to-raise-capital?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Announces $1.0 Million Private Placement of Common Stock and Warrants
July 30, 2026  |  quiverquant.comQ
60 Degrees updates strategy for ARAKODA and profitability
July 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-updates-strategy-for-arakoda-and-profitability?utm_source=marketbeat.com&utm_medium=referral
Interim Trial Plan Finalized for Tafenoquine Babesiosis Study
July 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/interim-trial-plan-finalized-for-tafenoquine-babesiosis-study?utm_source=marketbeat.com&utm_medium=referral
60 Degrees details tafenoquine priority review voucher strategy
June 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-details-tafenoquine-priority-review-voucher-strategy?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals, Inc. Partners with Runway Health to Offer ARAKODA® for Convenient Online Malaria Prevention
April 15, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Reports 65% Increase in FY 2025 Net Product Revenues to $1.0 Million and Operational Developments
March 31, 2026  |  quiverquant.comQ
60 Degrees Updates Affiliate Share Ownership Disclosure Error
March 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-updates-affiliate-share-ownership-disclosure-error?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Updates Legal Opinion for ATM Offering
March 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-updates-legal-opinion-for-atm-offering?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance Status
February 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-regains-nasdaq-listing-compliance-status?utm_source=marketbeat.com&utm_medium=referral
GoodRx Partners with 60 Degrees Pharmaceuticals to Offer Up to 30% Savings on ARAKODA® for Malaria Prevention
February 2, 2026  |  quiverquant.comQ
60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting Appeal
January 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-faces-immediate-nasdaq-delisting-appeal?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals Implements One-for-Four Reverse Split
January 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharmaceuticals-implements-one-for-four-reverse-split?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharma outlines growth strategy in investor webinar
January 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/60-degrees-pharma-outlines-growth-strategy-in-investor-webinar?utm_source=marketbeat.com&utm_medium=referral
60 Degrees Pharmaceuticals, Inc. Confirms Continuation of B-FREE Study to Assess ARAKODA® for Chronic Babesiosis Treatment
December 29, 2025  |  quiverquant.comQ
60 Degrees Pharmaceuticals Plans Expansion of Sales and Marketing Initiatives Following Positive Clinical Pilot Results
December 11, 2025  |  quiverquant.comQ

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRIW

$0.02 0.00 (-2.91%)
As of 09/23/2026 10:00 AM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Conduit Pharmaceuticals NASDAQ:CDTTW

$0.01 +0.00 (+28.28%)
As of 09/23/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Cingulate NASDAQ:CINGW

$0.0071 +0.00 (+5.99%)
As of 09/23/2026 11:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.03 -0.01 (-22.86%)
As of 09/23/2026 03:17 PM Eastern

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas